Overview

GTx, Inc. is a biopharmaceutical company. The Company is developing selective androgen receptor modulators (SARMs) , a drugs with the potential to prevents and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscles Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. In October 2012, it sold rights and related assets in the metastatic breast cancer product, Fareston, to ProStrakan Group plc.

Endorsements